Steven Cowart, MD
Endocrinology, Diabetes & Metabolism · Huntsville, ALNPI 1184675118
Payments from drug & device makers
Across 122 payments — averaging $14.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$660
- Medtronic$543
- Abbott$138
- Xeris Pharmaceuticals, Inc.$82
- Novo Nordisk$79
- BETA Bionics, Inc.$72
- plus $190 from 6 others
What the payments were for
- Food & beverage$1,764100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 45 | $660 |
| Medtronic(2 entities) | 45 | $543 |
| Abbott | 7 | $138 |
| Xeris Pharmaceuticals, Inc. | 4 | $82 |
| Novo Nordisk | 6 | $79 |
| BETA Bionics, Inc. | 4 | $72 |
| Corcept Therapeutics | 3 | $56 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Lilly USA, LLC | 2 | $37 |
| Novartis | 1 | $21 |
| AstraZeneca | 1 | $18 |
| AbbVie | 1 | $12 |
How this compares
$1,764 in reported general payments places this provider in the 15th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
See all endocrinology, diabetes & metabolism providers in Alabama →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 315 | $410,621 |
| MounjaroTirzepatide | 179 | $229,606 |
| Tresiba Flextouch U-200Insulin Degludec | 137 | $217,300 |
| OzempicSemaglutide | 136 | $209,041 |
| Humalog Kwikpen U-100Insulin Lispro | 487 | $186,710 |
| JanuviaSitagliptin Phosphate | 201 | $162,127 |
| JardianceEmpagliflozin | 121 | $128,596 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 41 | $121,985 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 710 | $117,260 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 92 | $111,889 |
| Tresiba Flextouch U-100Insulin Degludec | 118 | $98,582 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 152 | $95,234 |
| Novolog FlexpenInsulin Aspart | 278 | $92,876 |
| TradjentaLinagliptin | 100 | $88,587 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 75 | $68,689 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro, Humalog, Humulin 70-30 | $37 | $701,070755 claims |
| Novo NordiskOzempic, Rybelsus, Novolog, Fiasp | $79 | $299,073327 claims |
| Sanofi-aventis U.S. LLCLantus | $47 | $24,863199 claims |
| AbbVieSynthroid | $12 | $18,246230 claims |
| AstraZenecaFarxiga | $18 | $11,70912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 15th percentile of 79 endocrinology, diabetes & metabolism providers in Alabama.
Other endocrinology, diabetes & metabolism in Huntsville
- Dwain WoodeHuntsville$78K
- Ankur JindalHuntsville$6K
- Malapuram Vasudha ReddyHuntsville$6K
- Joshua TateHuntsville$5K
- Bobby JohnsonHuntsville$4K
- William GarveyBirmingham$3.8M
- Neil SchaffnerOpelika$642K
- Fernando OvalleBirmingham$516K
- Ralph TeagueBirmingham$487K
- Bantwal BaligaOpelika$483K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.